Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Reply to Letter to the Editor.

Literature DB >> 28939086

Reply to Letter to the Editor.

Jerry R Mendell¹.

Abstract

Year: 2017 PMID： 28939086 PMCID： PMC5628931 DOI： 10.1016/j.ymthe.2017.09.003

Source DB: PubMed Journal: Mol Ther ISSN： 1525-0016 Impact factor: 11.454

× No keyword cloud information.

14 in total

1. Dystrophin immunity in Duchenne's muscular dystrophy.

Authors: Jerry R Mendell; Katherine Campbell; Louise Rodino-Klapac; Zarife Sahenk; Chris Shilling; Sarah Lewis; Dawn Bowles; Steven Gray; Chengwen Li; Gloria Galloway; Vinod Malik; Brian Coley; K Reed Clark; Juan Li; Xiao Xiao; Jade Samulski; Scott W McPhee; R Jude Samulski; Christopher M Walker
Journal: N Engl J Med Date: 2010-10-07 Impact factor: 91.245

2. Follistatin gene delivery enhances muscle growth and strength in nonhuman primates.

Authors: Janaiah Kota; Chalonda R Handy; Amanda M Haidet; Chrystal L Montgomery; Amy Eagle; Louise R Rodino-Klapac; Danielle Tucker; Christopher J Shilling; Walter R Therlfall; Christopher M Walker; Steven E Weisbrode; Paul M L Janssen; K Reed Clark; Zarife Sahenk; Jerry R Mendell; Brian K Kaspar
Journal: Sci Transl Med Date: 2009-11-11 Impact factor: 17.956

3. Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes.

Authors: Jerry R Mendell; Zarife Sahenk; Samiah Al-Zaidy; Louise R Rodino-Klapac; Linda P Lowes; Lindsay N Alfano; Katherine Berry; Natalie Miller; Mehmet Yalvac; Igor Dvorchik; Melissa Moore-Clingenpeel; Kevin M Flanigan; Kathleen Church; Kim Shontz; Choumpree Curry; Sarah Lewis; Markus McColly; Mark J Hogan; Brian K Kaspar
Journal: Mol Ther Date: 2017-03-06 Impact factor: 11.454

Review 4. Novel therapeutic approaches for inclusion body myositis.

Authors: Thomas E Lloyd
Journal: Curr Opin Rheumatol Date: 2010-11 Impact factor: 5.006

5. Long-term observational study of sporadic inclusion body myositis.

Authors: Olivier Benveniste; Marguerite Guiguet; Jane Freebody; Odile Dubourg; Waney Squier; Thierry Maisonobe; Tanya Stojkovic; Maria Isabel Leite; Yves Allenbach; Serge Herson; Stefen Brady; Bruno Eymard; David Hilton-Jones
Journal: Brain Date: 2011-10-12 Impact factor: 13.501

6. Exercise induces a marked increase in plasma follistatin: evidence that follistatin is a contraction-induced hepatokine.

Authors: Jakob Hansen; Claus Brandt; Anders R Nielsen; Pernille Hojman; Martin Whitham; Mark A Febbraio; Bente K Pedersen; Peter Plomgaard
Journal: Endocrinology Date: 2010-11-10 Impact factor: 4.736

Reply to Letter to the Editor.

1. Dystrophin immunity in Duchenne's muscular dystrophy.

2. Follistatin gene delivery enhances muscle growth and strength in nonhuman primates.

3. Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes.

Review 4. Novel therapeutic approaches for inclusion body myositis.

5. Long-term observational study of sporadic inclusion body myositis.

6. Exercise induces a marked increase in plasma follistatin: evidence that follistatin is a contraction-induced hepatokine.

7. Inclusion body myositis. Observations in 40 patients.

8. Improvement in aerobic capacity after an exercise program in sporadic inclusion body myositis.

Review 9. Regulation of ovarian function by the TGF-beta superfamily and follistatin.

10. Neutralizing Antibodies Against Adeno-Associated Viral Capsids in Patients with mut Methylmalonic Acidemia.

Review 1. Myostatin/Activin Receptor Ligands in Muscle and the Development Status of Attenuating Drugs.